BioRepeller develops catheters that resist infection over several months. The coating is an actual barrier for binding of foreign material.
2M PICC lines (venous catheters) are inserted annually in the US for use in chemotherapy, blood transfusion and anti-biotic administration. 80,000 acquire serious infections in the hospital, of which 20,000 die. Today's technologies fail to prevent bacterial adhesion, biofilm formation and blood clooting.
The BioRepeller coating technology is developed by experienced scientists at Aarhus University, Denmark. Originally "anti-fouling" / "fouling patterns" for stem cell studies, the platform of FDA approved materials with a proprietory fabrication method is readily applied to polymers and metals.
The start-up team comprises two talented entrepreneurs and is backed by a strong advisory board of two scientific advisors and two commercial advisors. Novo Seeds granted 100k to cover testing through Q1-Q2 2014.